{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:44:32Z","timestamp":1786135472481,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2021-12374500"],"award-info":[{"award-number":["GR-2021-12374500"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.carrev.2026.07.022","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:51:58Z","timestamp":1785858718000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["De-escalation of antiplatelet therapy to evaluate platelet reactivity and clinical outcomes after coronary stenting in patients at high bleeding risk and recent acute coronary syndrome: Rationale and design of the DESC-HBR trial"],"prefix":"10.1016","author":[{"given":"Francesco","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Vizzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Zecchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Montalto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Carciotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Quadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Vergallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Castriota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuele","family":"Soraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Magliarditi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania Lo","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustina","family":"Iuvara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Munaf\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Giannino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pallante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Franzino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Teresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Varbella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Di Bella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Ortega-Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Micari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2026.07.022_bb0005","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.carrev.2026.07.022_bb0010","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.carrev.2026.07.022_bb0015","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.carrev.2026.07.022_bb0020","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.carrev.2026.07.022_bb0025","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.carrev.2026.07.022_bb0030","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41569-023-00901-2","article-title":"De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a consensus statement from an international expert panel on coronary thrombosis","volume":"20","author":"Gorog","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.carrev.2026.07.022_bb0035","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the academic research consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2026.07.022_bb0040","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2026.07.022_bb0045","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the PRECISE-DAPT score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2026.07.022_bb0050","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.carrev.2026.07.022_bb0055","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: the TROPICAL-ACS randomized trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2026.07.022_bb0060","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y\u2081\u2082 inhibitors in primary PCI","volume":"381","author":"DMF","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.carrev.2026.07.022_bb0065","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after PCI in patients with acute coronary syndrome: HOST-REDUCE-POLYTECH-ACS","volume":"396","author":"Kim","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2026.07.022_bb0070","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing PCI: TALOS-AMI","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2026.07.022_bb0075","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2026.07.022_bb0080","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.123.013242","article-title":"Short-term DAPT and DAPT de-escalation strategies for patients with acute coronary syndromes: a systematic review and network meta-analysis","volume":"16","author":"Kuno","year":"2023","journal-title":"Circ. Cardiovasc. Interv."},{"issue":"19","key":"10.1016\/j.carrev.2026.07.022_bb0085","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1161\/CIR.0000000000001285","article-title":"AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCCT\/SCMR\/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"150","author":"Thompson","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2026.07.022_bb0090","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor\u2013inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2026.07.022_bb0095","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","article-title":"Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease","volume":"64","author":"Angiolillo","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.carrev.2026.07.022_bb0100","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1253\/circj.CJ-19-1043","article-title":"Platelet-derived Thrombogenicity measured by Total Thrombus-formation analysis system in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"84","author":"Kikuchi","year":"2020","journal-title":"Circ. J."},{"key":"10.1016\/j.carrev.2026.07.022_bb0105","series-title":"Clinical Validation of the T-TAS 01 PL Assay in Patients Taking Antiplatelet Therapy. Paper presented at: ISTH 2020 Congress","author":"Dahlen","year":"2020"},{"issue":"22","key":"10.1016\/j.carrev.2026.07.022_bb0110","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1016\/j.jcin.2024.08.027","article-title":"International consensus statement on platelet function and genetic testing in percutaneous coronary intervention: 2024 update","volume":"17","author":"Angiolillo","year":"2024","journal-title":"JACC Cardiovasc. Interv."},{"issue":"23","key":"10.1016\/j.carrev.2026.07.022_bb0115","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.carrev.2026.07.022_bb0120","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.carrev.2026.07.022_bb0125","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1055\/a-1346-3300","article-title":"Pharmacodynamic profile and prevalence of bleeding episode in East Asian patients with acute coronary syndromes treated with prasugrel standard-dose versus de-escalation strategy: a randomized A-MATCH trial","volume":"121","author":"Jeong","year":"2021","journal-title":"Thromb. Haemost."},{"issue":"21","key":"10.1016\/j.carrev.2026.07.022_bb0130","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.jacc.2013.02.044","article-title":"Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status","volume":"61","author":"Amin","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.carrev.2026.07.022_bb0135","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of Ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.carrev.2026.07.022_bb0140","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/ehjcvp\/pvx032","article-title":"Rationale and design of the effectiveness of lower maintenance dose of ticagrelor early after myocardial infarction (electra)pilot study","volume":"4","author":"Kubica","year":"2018","journal-title":"Eur Heart J - Cardiovasc Pharmacother"},{"issue":"2","key":"10.1016\/j.carrev.2026.07.022_bb0145","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","article-title":"Bleeding avoidance strategies in percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.carrev.2026.07.022_bb0150","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2026.07.022_bb0155","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/eurheartj\/ehac706","article-title":"Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials","volume":"44","author":"Costa","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.carrev.2026.07.022_bb0160","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of Clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.carrev.2026.07.022_bb0165","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of Ticagrelor monotherapy vs Ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.carrev.2026.07.022_bb0170","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping aspirin within 1 month after stenting for Ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial","volume":"149","author":"Hong","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2026.07.022_bb0175","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2021.11.028","article-title":"Short duration of DAPT versus De-escalation after percutaneous coronary intervention for acute coronary syndromes","volume":"15","author":"Laudani","year":"2022","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.carrev.2026.07.022_bb0180","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur. Heart J."}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838926003349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838926003349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:44:23Z","timestamp":1786131863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838926003349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"alternative-id":["S1553838926003349"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2026.07.022","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De-escalation of antiplatelet therapy to evaluate platelet reactivity and clinical outcomes after coronary stenting in patients at high bleeding risk and recent acute coronary syndrome: Rationale and design of the DESC-HBR trial","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2026.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}